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Virus-mediated apoptosis is well documented in various systems, including herpes simplex virus 1 (HSV-1). HSV-2 is closely related to
HSV-1 but its apoptotic potential during infection has not been extensively scrutinized. We report that (i) HEp-2 cells infected with HSV-2(G)
triggered apoptosis, assessed by apoptotic cellular morphologies, oligosomal DNA laddering, chromatin condensation, and death factor
processing when a translational inhibitor (CHX) was added at 3 hpi. Thus, HSV-2 induced apoptosis but was unable to prevent the process
from killing cells. (ii) Results from a time course of CHX addition experiment indicated that infected cell protein produced between 3 and 5
hpi, termed the apoptosis prevention window, are required for blocking virus-induced apoptosis. This corresponds to the same prevention
time frame as reported for HSV-1. (iii) Importantly, CHX addition prior to 3 hpi led to less apoptosis than that at 3 hpi. This suggests that
proteins produced immediately upon infection are needed for efficient apoptosis induction by HSV-2. This finding is different from that
observed previously with HSV-1. (iv) Infected cell factors produced during the HSV-2(G) prevention window inhibited apoptosis induced by
external TNFa plus cycloheximide treatment. (v) NF-nB translocated to nuclei and its presence in nuclei correlated with apoptosis prevention
during HSV-2(G) infection. (vi) Finally, clinical HSV-2 isolates induced and prevented apoptosis in HEp-2 cells in a manner similar to that of
laboratory strains. Thus, while laboratory and clinical HSV-2 strains are capable of modulating apoptosis in human HEp-2 cells, the
mechanism of HSV-2 induction of apoptosis differs from that of HSV-1.
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Apoptosis is the purposeful process of cell suicide
characterized by distinct features including condensation
of the cell, maintenance of organelle integrity, and plasma
membrane blebbing (reviewed in Kerr et al., 1972;
Sanfilippo and Blaho, 2003). Apoptosis is also an important
cellular response to virus infection, and many viruses,
especially the large DNA viruses, have evolved mechanisms
to block the process (Koyama et al., 2000). Recently, a large
body of information has been generated which describes
apoptosis during HSV-1 infection (reviewed in Goodkin et
al., 2004). Briefly, HSV-1 triggers apoptosis and then later
infected cell proteins block the process from killing the cell,0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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and Blaho, 2001). The survival factors produced in this
‘‘prevention window’’ not only block apoptosis triggered by
the virus but also that stimulated by numerous external or
environmental pro-apoptotic treatments. The cellular tran-
scription factor NF-nB becomes activated during HSV-1
infection (Amici et al., 2001; Patel et al., 1998). While its
presence in nuclei correlates with apoptosis prevention
(Goodkin et al., 2003; Gregory et al., 2004; Medici et al.,
2003), alternative roles for NF-nB during HSV-1 infection
have also been proposed (Taddeo et al., 2002). Conversely,
the status of apoptosis during HSV-2 infection is much less
clear.
When Koyama et al. looked at apoptosis during HSV-2
infection, they observed a small but significant level of
apoptosis in HSV-2-infected HEp-2 cells, in contrast to
HSV-1 (Koyama et al., 1998). Apoptotic features were also05) 297 – 310
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lumbar spinal cord (Ozaki et al., 1997), pituitary gland,
peritoneal macrophages (Fleck et al., 1999), monocytoid
(Mastino et al., 1997), and dendritic cells (Jones et al.,
2003). Together, these observations seem to imply that
infection with wild-type HSV-2 leads to apoptotic cell
death. A series of experiments by Jerome and Corey showed
that HSV-2 was unable to block antigen-specific CD4+
cytotoxic T-lymphocyte (Jerome et al., 1998)-, UV-, and
anti-Fas antibody (Jerome et al., 1999)-induced apoptosis,
suggesting that differences exist between HSV-1 and HSV-2
in their ability to inhibit apoptosis. Consistent with these
observations is the finding that HSV-2, but not HSV-1,
blocks the surface expression and activity of Fas ligand
(Sieg et al., 1996). However, others have concluded that
HSV-2 can indeed prevent apoptosis in a manner similar to
HSV-1 and the viral US3 protein kinase (Asano et al., 1999;
Hata et al., 1999) and ribonucleotide reductase (Langelier et
al., 2002; Perkins et al., 2003) participate in the blocking.
One explanation for such apparent inconsistencies is that the
HSV-2 anti-apoptotic effect may result from laboratory
adaptation since primary clinical HSV-2 isolates were
reported to be unable to block apoptosis (Jerome et al.,
2001). These issues described above indicate the status of
apoptosis during HSV-2 infection is currently unresolved.
The goal of this study is to determine whether HSV-2
strains have the ability to modulate apoptosis during
infection. We show that both clinical and laboratory HSV-
2 strains induced and subsequently blocked apoptosis in
infected HEp-2 cells. HSV-2-infected cell proteins synthe-
sized between 3 and 5 hpi were required for blocking
apoptosis triggered either by virus infection or environ-
mental TNFa plus cycloheximide treatment. NF-nB trans-
located to the nuclei of HSV-2-infected cells and this
correlated with apoptosis prevention. In contrast to HSV-1,
optimal HSV-2-induced apoptosis appeared to required
infected cell proteins produced immediately upon infection.
Together, these results imply that the prevention of
apoptosis by HSV-2 and HSV-1 is similar, but the
mechanism or efficiency of induction by the two viruses
may differ.Results
Induction and prevention of apoptosis in HSV-2(G)-infected
HEp-2 cells
HEp-2 cells infected with wild-type HSV-1 in the
presence of CHX die of apoptosis (Aubert and Blaho,
1999; Koyama and Adachi, 1997). While IE gene expres-
sion triggers apoptosis in HSV-1-infected cells (Sanfilippo
et al., 2004), infected cell proteins produced between 3 and
6 hpi in an apoptosis ‘‘prevention window’’ prevent the
process from killing the infected cells (Aubert et al., 1999).
In this manner, HSV-1 modulates the programmed cell deathprocess during its productive replication cycle (Aubert and
Blaho, 2001; Goodkin et al., 2004). The goal of this study
was to determine whether HSV-2-infected HEp-2 cells
manipulate apoptosis in a similar manner to that described
for HSV-1-infected cells.
To investigate apoptosis during HSV-2 infection, we
performed three series of experiments. In the first set, HEp-2
cells were mock-infected, infected with HSV-1(F) or HSV-
2(G), and either subjected to CHX additions at 3 and 6 hpi
or not treated at all. For control purposes, mock-infected
cells were maintained in the presence and absence of CHX
to reveal any background levels of apoptosis due to CHX. In
addition, TNFa plus CHX (TNFa/CHX) were added to
cells at 0 hpi as a positive control. At 17 hpi, live cells were
stained with Hoechst DNA dye and subsequently visualized
by microscopy to observe nuclear and cellular morphologies
as described in Materials and methods. Intense, compact
nuclear blue fluorescent staining corresponds to cells that
have condensed chromatin, a characteristic of apoptosis
(Aubert and Blaho, 1999). Apoptotic cells also display
various morphological characteristics, such as membrane
blebbing, cell shrinkage, nuclear condensation, and chro-
matin margination which are readily visualized by standard
light microscopy (Kerr et al., 1972; Sanfilippo and Blaho,
2003). The results (Fig. 1A) were as follows.
As expected (Aubert and Blaho, 1999), little to no
apoptotic features were observed in mock-infected cells in
the absence and presence of CHX (2% and 7% condensed
chromatin, respectively) (Fig. 1A, panels 1 and 3). Almost
complete condensation of chromatin (94%) and cell
shrinkage/membrane blebbing occurred in the control
TNFa/CHX-treated cells (panels 5 and 6). Cytopathic effect
was observed with HSV-1(F) and HSV-2(G) in the absence
of CHX (compare panel 2 with panels 8 and 14). The
addition of CHX at 3 hpi to HSV-1(F)- and HSV-2(G)-
infected cells resulted in dramatic increases in condensed
chromatin (69% and 67%, respectively) with many cells
showing apoptotic morphologies (panels 9, 10 and 15, 16).
Thus, when infected cell protein synthesis is prevented at 3
hpi (by addition of CHX), the infected cells readily die.
Comparison of the HSV-1- and HSV-2-infected cells with-
out and with the addition of CHX at 3 hpi demonstrated a
dramatic increase in cells displaying condensed chromatin
(from 6% to 69% for HSV-1(F) and from 5% to 67% for
HSV-2(G)). This represents an approximately 12-fold
difference for HSV-2 and a 10-fold change for HSV-1,
demonstrating that the effects are similar for the two viruses.
The addition of CHX at 6 hpi resulted in a significant
decrease in the number of cells undergoing apoptosis (an
approximately 30–40% drop) compared to CHX addition at
3 hpi (compare 12, 18 with 10, 16). These findings imply
that HSV-2(G) may be capable of inducing apoptosis in
HEp-2 and that proteins necessary for apoptosis prevention
may be synthesized prior to 6 hpi.
In the next set of experiments, we further investigated
these results from a biochemical standpoint. The cells shown
Fig. 1. Infected cell morphologies (A) and immunoblots of infected cell proteins (B) and death factors (C). Mock-, HSV-1(F)-, and HSV-2(G)-infected cells
(MOI of 10 PFU/cell) were either CHX treated, CHX/TNFa treated, or not treated at all () at the corresponding times indicated. Phase-contrast and Hoechst
(H33258)-stained fluorescence images were obtained at 17 hpi (A). White numbers in the right corners correspond to the number of apoptotic cells
(magnification40). Whole cell extracts were prepared at 18 hpi, separated in a denaturing gel, transferred to nitrocellulose, and probed with anti-ICP4, anti-a-
tubulin (A), anti-PARP, and anti-caspase-3 (B) antibodies. Percentage of PARP cleavage was determined using NIH image. Locations of molecular mass (kDa)
markers are indicated in the margins.
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prepared, separated in a denaturing gel, transferred to
nitrocellulose, and probed using anti-ICP4, anti-PARP, and
anti-caspase-3 antibodies as described in Materials and
methods. Blots were also probed with an anti-a-tubulin
antibody as a loading control to ensure that each lane
received an equal amount of protein (data not shown). ICP4was used as a marker for infection since the slight mobility
shift of ICP4 allows us to unambiguously differentiate
between HSV-1- and HSV-2-infected cells (Blaho and
Roizman, 1991; Blaho et al., 1994). During apoptosis, the
inactive form of caspase-3 (procaspase-3) becomes cleaved
and PARP is processed from its full-length 116-kDa form to
a cleaved product of 85 kDa (Sanfilippo and Blaho, 2003); in
Fig. 2. Nucleosomal laddering of chromosomal DNA was extracted from
HSV-1(F)-, HSV-2(G)-, and mock-infected HEp-2 cells (MOI of 10 PFU/
cell). Cells were either treated with CHX (10 Ag/Al), TNFa/CHX (10 Ag/
Al), or not at all () at the times indicated. DNA was extracted at 22 hpi,
separated in a 1.5% agarose gel containing ethidium bromide (0.1% Ag/ml),
and visualized under UV illumination.
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Materials and methods) and the loss of anti-caspase-3
antibody reactivity are indicative of apoptotic processing.
While ICP4 from HSV-1 and HSV-2 was synthesized to
abundant levels in infected cells in the absence of CHX
(Fig. 1B, lanes 5 and 8), levels of ICP4 significantly
decreased when CHX was added at 3 hpi (lanes 6 and 9).
ICP4 levels approached that of non-treated cells when CHX
was added at 6 hpi (compare lanes 5, 8 with lanes 7, 10).
Mock-infected cells in the presence and absence of CHX
revealed background levels (10% and 12%) of PARP
cleavage (Fig. 1C, lanes 2 and 3) and no caspase-3
activation (lanes 2 and 3). The most PARP cleavage
(74%) was found with control TNFa/CHX added at 0 hpi
(lane 4). The amount of PARP and caspase-3 cleavage in
HSV-1(F)- and HSV-2(G)-infected cells in the absence of
CHX was comparable to mock-infected cells (compare lanes
5 and 8 with lane 2). The addition of CHX at 3 hpi to HSV-
1- and HSV-2-infected cells resulted in an approximately
five-fold increase of PARP cleavage compared to non-
treated cells (compare lane 5 with lane 6 and lane 8 with
lane 9). When CHX was added at 6 hpi, the percentage
of PARP cleavage was reduced from 67% to 34% in
HSV-1-infected cells (lanes 6 and 7) and 58% to 29% in
HSV-2-infected cells (lanes 8 and 10), representing an
approximately 2-fold difference for each virus. Caspase-3
activation appeared to mirror these observations as the
disappearance of caspase-3 increased significantly when
CHX was added at 3 hpi (lanes 6 and 9).
In the final set of experiments, HEp-2 cells mock
infected or infected with HSV-1(F) or HSV-2(G) were
treated with CHX or TNFa/CHX as in Fig. 1, then
harvested at 22 hpi, and a DNA fragmentation assay (Fig.
2) was performed as described in Materials and methods.
Mock-infected cells with no treatment resulted in a very
minimal amount of fragmentation (Fig. 2, lane 1) while cells
treated with TNFa/CHX at 0 hpi resulted in the most
fragmentation, as evidenced by a smear (lane 3). The
progression from a defined oligonucleotide ladder at early
times of apoptosis followed by a definitive smear later is
standard for HEp-2 cells (Aubert and Blaho, 1999; Nguyen
et al., 2005). Non-treated HSV-1(F)- and HSV-2(G)-infected
cells displayed fragmentation similar to that of control
mock-infected cells (compare lanes 4 and 8 with lanes 1 and
2). The amount of DNA fragmentation increased signifi-
cantly in HSV-1(F)- and HSV-2(G)-infected cells treated
with CHX at 3 hpi, comparable to that with TNFa/CHX
(compare lanes 5 and 7 with lane 3), while CHX addition at
6 hpi was much reduced (lanes 6 and 9). It should be noted
that since these were low molecular weight DNA prepara-
tions, increased total DNA, as observed in lanes 3, 5, and 7,
corresponds to DNA liberated during apoptosis (Aubert and
Blaho, 1999; Nguyen et al., 2005). Based on all of these
findings, we can conclude that HSV-2(G) has the ability to
first induce and then block apoptosis. When CHX was
added at 3 hpi, apoptosis was triggered in the infected cellsbut they died because they were unable to synthesize
sufficient levels of the necessary proteins required to block
the death process, yielding morphological, biochemical, and
genetic apoptotic features.
Determination of the HSV-2(G) apoptosis prevention
window time frame
As previously described (Aubert et al., 1999) and
observed above, wild-type HSV-1 induces but then blocks
apoptosis and this prevention requires de novo synthesis of
infected cell proteins between 3 and 5 hpi (Moy and Blaho,
unpublished results). Since HSV-2 has a faster rate of
infection then HSV-1 in cultured cells (Blaho and Roizman,
1991; Blaho et al., 1994), we needed to examine the kinetics
of apoptosis prevention by HSV-2(G). HEp-2 cells were
mock infected or infected with HSV-2(G) and CHX was
either not added or added at various time points during
infection (0–8 hpi) to block de novo protein synthesis.
Whole cell extracts were prepared at 21 hpi, separated on a
denaturing gel, transferred to nitrocellulose, and probed
using anti-ICP4, anti-a-tubulin, anti-PARP, and anti-cas-
pase-3 antibodies as described in Materials and methods.
We probed for a-tubulin as a loading control to ensure that
every lane received equal amounts of protein. The results
(Fig. 3) were as follows.
The level of ICP4 detected in HSV-2(G)-infected cells in
the absence of CHX was comparable to that observed when
Fig. 3. Identification of the HSV-2(G) apoptosis prevention window. Whole cell extracts were prepared at 22 hpi from mock-infected cells or cells infected with
HSV-2(G) (MOI of 10 PFU/cell), separated in a denaturing gel, transferred to nitrocellulose, and probed with anti-ICP4, anti-a-tubulin, anti-PARP, and anti-
caspase-3 antibodies. Infected cells were treated (+) with CHX (10 Ag/Al) at the times indicated or not treated at all (). Mock-infected cells treated with CHX
(10 Ag/Al) were used as a control. PARP cleavage was quantified using NIH Image. Locations of molecular mass (kDa) markers are indicated in the left margin.
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lanes 11 and 12). In contrast, the addition of CHX at 0–3
hpi greatly diminished the amounts of ICP4, indicating
CHX succeeded in blocking newly synthesized protein.
Mock-infected cells, as well as the mock-infected cells with
CHX added at 0 hpi, showed low background levels (5%
and 11%, respectively) of PARP cleavage (lanes 2 and 3).
Cells infected with HSV-2(G) without treatment showed
PARP cleavage levels (7%) similar to that of mock-infected
(5%) cells (compare lane 4 and lane 2), reiterating that HSV-
2(G), in the absence of CHX, does not show features of
apoptosis. In contrast, the amount of caspase-3 in the HSV-
2(G)-infected cells was slightly less than that of mock
(compare lane 4 with lane 2). A similar partial loss of
caspase-3 was observed during wild-type HSV-1 infection
(Aubert et al., 1999) and implies the induction of ‘‘abortive
apoptosis’’ during infection with these viruses (Goodkin et
al., 2004).
Maximum PARP cleavage (52% and 61%) was observed
during HSV-2(G) infection when CHX was added at 2 and 3
hpi (lanes 6 and 7). While the levels of PARP cleavage
observed with the 0- and 1-hpi CHX additions (25% and
26%, respectively) were significantly greater than the
control mock (5%) and untreated infected (7%) cells
(compare lanes 5, 6 with lanes 2, 4), they were not
maximum. This finding was surprising since we (Aubert
and Blaho, 1999; Aubert et al., 1999) and others (Koyama
and Adachi, 1997) have repeatedly observed that CHX at
the time of HSV-1 infection (0 hpi) results in maximum
apoptosis. Cleavage of caspase-3 mirrored the PARP
processing results, inasmuch as maximum caspase-3 loss
was observed when CHX was added at 2 and 3 hpi (lanes 7
and 8). We have repeated this time course of CHX addition
experiment five separate times and observed the exact samephenomena (data not shown). That maximum apoptosis
with HSV-2(G) occurs when CHX is added at 2 or 3 hpi and
suggests a difference in apoptosis modulation between these
two viruses.
The cells used above were also visualized at 21 hpi by
phase-contrast microscopy prior to extraction (data not
shown). Mock-infected cells with no treatment displayed no
characteristics of apoptosis, while TNFa/CHX treatment
resulted in almost 100% of the cells displaying characteristic
apoptotic morphologies. HSV-2(G)-infected cells that
received no CHX treatment displayed cytopathic effect
and did not appear to be apoptotic. During HSV-2(G)
infection, the percentage of cells that appeared apoptotic
increased as CHX was added at each sequential hour until 6
hpi, thus corroborating our biochemical data above. Based
on these results, we conclude the HSV-1(G) apoptosis
prevention window is between 3 and 5 hpi. This time frame
is the same as that observed for HSV-1 (Aubert and Blaho,
2001; Aubert et al., 1999).
HSV-2(G)-infected cells fail to block TNFa plus CHX
apoptotic stimulus when applied at 3 hpi
The previous studies above focused on the ability of
HSV-2 to prevent apoptosis that was triggered by infection
with the virus itself. However, apoptosis can be caused by a
variety of internal and external triggers (reviewed in
Sanfilippo and Blaho, 2003) and HSV-1 has been shown
to prevent cell death induced by many of these agents
(Galvan and Roizman, 1998; Goodkin et al., 2003; Jerome
et al., 1998; Koyama and Miwa, 1997). We were partic-
ularly interested in determining what effect the addition of
TNFa plus CHX would have on HSV-2(G)-infected HEp-2
cells since we previously reported that infected cell proteins
Fig. 5. HSV-2(G) prevention of TNFa/CHX-dependent apoptotic death
factor processing. Whole cell extracts were prepared at 20 hpi from mock-,
HSV-1(F)-, and HSV-2(G)-infected cells (MOI of 10 PFU/cell), separated
on a denaturing gel, transferred to nitrocellulose, and probed with anti-
ICP4, anti-a-tubulin (A), anti-PARP, and anti-caspase-3 (B) antibodies.
Cells were either treated with CHX (10 Ag/Al), TNFa/CHX (10 Ag/Al)
treated, or not treated at all () at the indicated times. Percentage of PARP
cleavage was determined by NIH Image. Locations of molecular mass
(kDa) markers are indicated in the margins.
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apoptosis induced by these agents (Goodkin et al., 2003).
HEp-2 cells were mock, HSV-1(F), or HSV-2(G) infected
(MOI = 10 PFU/cell) and either treated with TNFa/CHX at
3 hpi and 6 hpi or not treated at all. At 20 hpi, cells were
stained with Hoechst DNA dye and observed by phase-
contrast and florescence microscopy to visualize cellular
and nuclear morphologies (Fig. 4).
Untreated and CHX-treated mock-infected cells
appeared flat, elongated, and their nuclei appeared round
(Fig. 4, panels 1, 3 and 2, 4) while close to 100% of those
treated with TNFa/CHX displayed morphologies character-
istic of apoptosis, including cell shrinkage, membrane
blebbing (panel 5), and chromosome condensation (panel
6). HSV-1(F)- and HSV-2(G)-infected cells displayed
cytopathic effect due to infection; however, these cells did
not appear apoptotic (compare panels 7, 8 and 13, 14 with
panels 5, 6). When TNFa/CHX was added at 3 hpi to HSV-
1(F)- and HSV-2(G)-infected cells, the number of cells that
appeared apoptotic increased dramatically (panels 9, 10 and
15, 16); HSV-2(G) plus CHX at 3 hpi had 79% cells with
condensed chromatin compared to 5% in the untreated
infection. The numbers of apoptotic cells decreased when
TNFa/CHX was added at 6 hpi to infected cells (panels 11,
12 and 17, 18); 26% of HSV-2(G)-infected cells had
condensed chromatin. These results suggest that HSV-
2(G) can prevent TNFa/CHX-induced apoptosis in a
manner similar to that of HSV-1.
To biochemically confirm these findings, whole cell
extracts were prepared from the cells described above. Cells
were harvested at 21 hpi, separated on a denaturing gel,
transferred to nitrocellulose, and immunoblots were per-
formed using anti-ICP4, anti-a-tubulin (Fig. 5A), anti-Fig. 4. HSV-2(G) prevention of TNFa/CHX-dependent apoptotic morphologies. H
cell) for 19 h. Cells were treated with either CHX (10 Ag/Al), TNFa/CHX (10 Ag/Al
visualized using fluorescence (Hoechst H33258) and phase-contrast microscopy (
number of apoptotic cells.PARP, and anti-caspase-3 (Fig. 5B) antibodies. a-Tubulin
was used as loading control to ensure equal protein
concentration in each lane. The maximum amounts ofEp-2 cells were mock, HSV-1(F), and HSV-2(G) infected (MOI of 10 PFU/
), or not at all at the times indicated. Nuclear and cellular morphologies were
magnification, 40). White numbers in the right corners correspond to the
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infection had occurred, were seen in non-treated cells
(Fig. 5A, lanes 4 and 7). ICP4 levels significantly
decreased when TNFa/CHX was added at 3 hpi (lanes
5 and 8) and they approached non-treated levels when
TNFa/CHX was added at 6 hpi (lanes 6 and 9). Mock-
infected cells in the absence or presence of CHX showed no
PARP cleavage except background (3%) levels (Fig. 5B,
lanes 1 and 2). The addition of TNFa/CHX to mock-
infected cells resulted in almost complete (94%) PARP
cleavage (lane 3).
PARP cleavage in HSV-1- and HSV-2-infected cells in
the absence of treatment revealed only background levels
(4%) comparable to mock (Fig. 5B, compare lanes 4 and 7
with lane 1). When TNFa/CHX was added at 3 hpi to HSV-
1- and HSV-2-infected cells, PARP cleavage significantly
increased (92% and 79%, respectively), resembling that of
mock-infected cells treated with TNFa/CHX (compare
lanes 5 and 8 with lane 3). Under these conditions, there
was also complete disappearance of caspase-3 (lanes 3, 5,
and 8). The maximum amount of PARP cleavage observed
for the 3-hpi treatment with HSV-2(G) was not as high as
that with HSV-1(F). This difference is similar to that
observed in Fig. 1B with CHX treatment at 3 hpi and
may suggest that HSV-1 is a more potent inducer of
apoptosis than HSV-2. The amount of PARP and caspase-3
processing decreased when TNFa/CHX was added at 6 hpi
in HSV-1 (92–66% PARP cleavage)- and HSV-2 (79–51%
PARP cleavage)-infected cells. Taking these observations
together, we can conclude that HSV-2(G) is able to prevent
apoptosis induced by TNFa/CHX and the infected cell
proteins required for this effect are synthesized between 3
and 6 hpi. This time frame corresponds to the HSV-2(G)
apoptosis prevention window (Fig. 3).Fig. 6. HSV-2(G) infection induces NF-nB nuclear localization. HEp-2 cells seede
PFU/cell), fixed for indirect immunofluorescence at 8 hpi, and double stained with
were either treated with CHX (10 Ag/Al) or TNFa/CHX (10 Ag/Al) at the times indi
secondary antibodies, respectively. Arrows mark representative localizations of NNF-jB localization to nuclei during HSV-2(G) infection
requires infected cell proteins synthesized prior to 6 hpi and
correlates with apoptosis prevention
The nuclear localization of the transcriptional regulatory
factor NF-nB during HSV-1 infection has been extensively
studied (Amici et al., 2001; Goodkin et al., 2003; Patel et
al., 1998). We wished to examine the nuclear localization of
NF-nB in HSV-2-infected HEp-2 cells using indirect
immunofluorescence and immunoblotting techniques. Ini-
tially, HEp-2 cells were mock-, HSV-1(F)-, and HSV-2(G)-
infected (MOI = 10), treated with CHX at 3, 6 hpi, or left
untreated and, at 8 hpi, fixed with formaldehyde/acetone for
indirect immunofluorescence analyses as described in
Materials and methods. Cells were double stained with a
monoclonal antibody against NF-nB plus a polyclonal
antibody specific for the IE viral protein ICP22 of HSV-1
and HSV-2 (Blaho et al., 1997). The results (Fig. 6) were as
follows.
NF-nB remained in the cytoplasm of mock-infected cells
in the absence and presence of CHX (Fig. 6, panels 1 and
3). When control TNFa/CHX was added to mock-infected
cells, NF-nB was found mainly in nuclei (panel 5), as
expected (Beg et al., 1993; Goodkin et al., 2003; Wallach et
al., 1999). At 8 hpi following HSV-2(G) infection alone,
numerous cells showed nuclear NF-nB staining; the most
intensely stained cells (panel 13) were those that also had
high levels of nuclear ICP22 (panel 14). While CHX
addition at 3 hpi did not yield a significant decrease in the
levels of ICP22 in infected cells (panel 16), all NF-nB was
cytoplasmic (panel 15). When CHX was added at 6 hpi,
NF-nB was detected in the nuclei to the same extent as
those infected cells in the absence of CHX (compare panels
17 and 13). These results imply that HSV-2(G)-infected celld on coverslips were mock, HSV-1(F), and HSV-2(G) infected (MOI of 10
monoclonal anti-NF-nB and polyclonal anti-ICP22 antibodies. HEp-2 cells
cated. NF-nB and ICP22 were observed with FITC- and AMCA-conjugated
F-nB (magnification, 100).
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NF-nB.
To biochemically confirm these results and to assess
apoptotic status, HEp-2 cells were infected and treated as
above but at 22 hpi, cells were harvested, nuclear and
cytoplasmic extracts were prepared, separated on a denatur-
ing gel, transferred to nitrocellulose, and probed with anti-
ICP4 (Fig. 7A), anti-NF-nB (Fig. 7B), anti-PARP, anti-
caspase-3 (Fig. 7C) antibodies. To ensure that contamination
of the subcellular fractions did not occur, the immunoblot
was also probed for a-tubulin (cytoplasmic marker) and
Lamin B (nuclear marker). These proteins were detected
exclusively in their respective lanes (data not shown); the
only exception was that low levels of a-tubulin were found
in the nuclear lane of mock-infected cells treated with
TNFa/CHX, presumably due to extensive cell death
occurring in these cells (Morton and Blaho, unpublished
results).
ICP4 predominated in nuclei and its level decreased
when CHX was added at 3 hpi (Fig. 7A, lane 14) compared
to no treatment (lane 12) or when CHX was added at 6 hpi
(lane 16). In the absence of treatment, infection with HSV-
2(G) resulted in more NF-nB in the nuclear fraction than the
cytoplasmic fraction (Fig. 7B, lanes 12 and 13). When CHX
was added at 3 hpi, the majority of NF-nB remained in the
cytoplasmic fraction (lane 15). The addition of CHX at 6 hpi
revealed an equal, if not greater, amount of NF-nB in theFig. 7. NF-nB partitioning in nuclear fractions correlates with apoptosis preventio
with HSV-1(F) or HSV-2(G) (MOI of 10 PFU/cell), harvested at 20 hpi, nuclea
transferred to nitrocellulose, and probed with anti-ICP4 (A), anti-NF-nB (B), anti-
Ag/Al), TNFa/CHX (10 Ag/Al), or not at all () at the times indicated. Location
harvesting, infected cell morphologies (D) were visualized by phase-contrast micnuclear than in the cytoplasmic fractions (lanes 16 and 17).
This behavior in HSV-2(G)-infected cells was similar to that
observed with HSV-1(F) (lanes 6–11). Based on these
results, we conclude that NF-nB translocates to nuclei
during HSV-2(G) infection and infected cell proteins
synthesized after 3 hpi are needed for this to occur.
The indirect immunofluorescence experiments above
(Fig. 6) were performed prior to a time when the cells
would show features of apoptosis. To investigate cellular
death factor processing and nuclear localization of NF-nB,
we also probed the immunoblot (Figs. 7A and B) for PARP
and caspase-3. Finally, phase-contrast microscopic images
were documented prior to harvesting the cells (Fig. 7D). As
expected, mock-infected cells in the absence of treatment
revealed no PARP cleavage or caspase-3 activation (Fig. 7C,
lanes 2 and 3). In contrast, mock-infected cells treated with
TNFa/CHX showed almost 100% PARP cleavage, com-
plete activation of caspase-3 (lanes 4 and 5), and showed
apoptotic cell morphologies (Fig. 7D). HSV-2(G)-infected
cells in the absence of CHX showed only background levels
of PARP cleavage, relatively no caspase-3 processing (lanes
12 and 13), and non-apoptotic CPE (Fig. 7D). The addition
of CHX at 3 hpi to HSV-2(G)-infected cells resulted in
significant PARP cleavage and enhanced caspase-3 activa-
tion (lane 15), while processing of these factors was reduced
when CHX was added at 6 hpi (lane 17). Accordingly, the 6-
hpi CHX addition showed less apoptotic morphologies withn during HSV-2(G) infection. HEp-2 cells were mock infected or infected
r and cytoplasmic fractions were prepared, separated in a denaturing gel,
PARP, and anti-caspase-3 (C) antibodies. Cells were treated with CHX (10
s of molecular mass (kDa) markers are indicated in the margins. Prior to
roscopy (magnification, 40).
J.C. Yedowitz, J.A. Blaho / Virology 342 (2005) 297–310 305HSV-2(G) than the 3-hpi addition (Fig. 7D). Thus, when cell
death was maximum (Fig. 7C, lane 15), NF-nB was
cytoplasmic (Fig. 7B, lane 15). When apoptosis was
prevented by the virus, either without treatment (Fig. 7C,
lane 13) or with the 6-hpi CHX addition (Fig. 7C, lane 17),
NF-nB was detected in nuclei (Fig. 7B, lanes 12 and 16).
Taken together, these results indicate that nuclear trans-
location of NF-nB during HSV-2(G) infection correlates
with apoptosis prevention. As similar conclusion was drawn
for HSV-1 infection (Goodkin et al., 2003; Gregory et al.,
2004).
Apoptosis modulation by HSV-2 clinical isolates
All of the results above were obtained using the
laboratory HSV-2(G) strain. It has been reported that
laboratory-adapted strains of HSV-2 had weaker anti-
apoptotic capability against certain environmental agents
than HSV-1 (Jerome et al., 1998) and primary clinical
isolates showed no inhibitory activity (Jerome et al., 2001).
Due to this issue of whether HSV-2 clinical isolates have the
ability to induce or prevent apoptosis, we set out to
determine (i) if apoptosis can occur in HEp-2 cells infected
with HSV-2 clinical isolates and (ii) its extent when
compared to HSV-1 and HSV-2 control viruses. HEp-2
cells were either mock infected or infected (MOI = 10 PFU/
cell) with HSV-1(F), HSV-1(TC), HSV-2(G), HSV-2(333),
HSV-2(C2), or HSV-2(C9). TC is an HSV-1 clinical isolate,
while C2 and C9 are HSV-2 clinical isolates. 333 was used
as an alternative laboratory strain, for comparison to strain
HSV-2(G). Infected cells were either treated with CHX at 3
hpi or not treated at all. At 19 hpi, cells were stained with
Hoechst DNA dye and nuclear and cellular morphologies
were visualized (Fig. 8).
Mock-infected cells in the absence and presence of CHX
had oval nuclei (Fig. 8, panels 1 and 3) and appeared flat
and elongated (panels 2 and 4). All infected cells in the
absence of CHX displayed effects of cytopathic effect,
appearing rounded (panels 6, 10, 14, 18, 22, 26) with
evidence of chromatin margination (panels 5, 9, 13, 17, 21,
25); this latter feature was quite apparent with HSV-1(F).
The extents of detectable chromatin condensation in these
cells were less than 13%. The addition of CHX at 3 hpi
resulted in cells displaying apoptotic characteristics includ-
ing, chromatin condensation (panels 7, 11, 15, 19, 23, 27),
membrane blebbing, and cell shrinkage (panels 8, 12, 16,
20, 24, 28). Both laboratory HSV-1(F) and the clinical
isolate HSV-1(TC) had significant amounts of condensed
chromatin (75% and 51%, respectively), while the two
laboratory HSV-2 strains, G and 333, had equal amounts
(66% and 70%). The two clinical HSV-2 strains, C2 and
C9, had condensed chromatin levels similar to that of the
other viruses (58 and 68%, respectively). These findings
suggest that the capacity of the clinical virus isolates to
induce apoptosis was similar to that of the laboratory
strains.To biochemically confirm these observations, whole cell
extracts of the cells above were made at 20 hpi, separated on
a denaturing gel, transferred to nitrocellulose. and probed
with anti-ICP4, anti-a-tubulin (Fig. 9A), anti-PARP, and
anti-caspase-3 (Fig. 9B) antibodies. High levels of ICP4
were detected in all virally infected cells in the absence of
CHX addition, indicating productive infections. The levels
of ICP4 were reduced by the addition of CHX at 3 hpi,
confirming the inhibition of protein synthesis. Mock-
infected cells with and without CHX did not show PARP
cleavage above background (4% and 6% cleavage) levels
(Fig. 9, lanes 2 and 3). In the absence of CHX, infected cells
did not exhibit PARP cleavage above 17%. While HEp-2
cells infected with HSV-2 clinical isolates C2 and C9
showed minimal PARP and caspase-3 cleavage in the
absence of CHX (lanes 12 and 15), the addition of CHX
at 3 hpi caused the amount of apoptosis to increase
approximately four-fold (lanes 13 and 14). Importantly,
the PARP processing and caspase-3 activation observed
with C2 (63%) and C9 (66%) plus CHX was equivalent to
that of the HSV-2 laboratory strains, G (64%) and 333
(69%) (compare lanes 13, 14 with lanes 9, 11). Thus, we
conclude that HSV-2 clinical and laboratory strains are able
to induce and then prevent apoptosis in infected HEp-2 cells
in the same manner.Discussion
While the details of apoptosis during HSV-1 infection
have become more defined in recent years, issues regarding
the association of HSV-2 with the programmed cell death
process remain unresolved. Our goal was to directly test
whether HSV-2 could modulate apoptosis during its
productive replication cycle. Our key findings may be
summarized as follows.
HSV-2 first triggers and then prevents apoptosis during
productive infection
This conclusion is based on the observation that
significant apoptosis occurs during HSV-2 infection if
CHX is added at 3 hpi but not if the drug is added at 6
hpi. This implies that upon infection, the cells begin the
concerted cascade of apoptosis, and if the appropriate anti-
apoptotic proteins are not synthesized, cell death occurs. We
observed this effect with two laboratory strains, HSV-2(G)
and HSV-2(333), as well as with two HSV-2 and one HSV-1
clinical isolates. That there was a significant decrease in the
number of cells that died of apoptosis when CHX is added
at 6 hpi demonstrates that proteins needed to prevent
apoptosis were synthesized prior to that time. Our detailed
time course of CHX addition experiment demonstrated that
proteins produced in a window between 3 and 5 h of HSV-2
infection are required for blocking virus-induced cell death.
Thus, these studies show that HSV-2 has the ability to
Fig. 8. Nuclear and cellular morphologies of cells infected with clinical HSV-2 isolates. HEp-2 cells were infected with HSV-1(F), HSV-2(G), HSV-2(333), and
clinical isolates HSV-1(TC), HSV-2(C2), HSV-2(C9) (MOI of 10 PFU/cell), or mock infected. Cells were either treated (+) with CHX (10 Ag/Al) at 3 hpi or not
at all. At 19 hpi, cells were visualized using fluorescence (Hoechst H33258) and phase-contrast microscopy (magnification, 40). White numbers in the right
corners correspond to the number of apoptotic cells. Locations of molecular mass (kDa) markers are indicated in the margins.
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ability mirrors that of HSV-1 (Aubert et al., 1999).
It is perhaps not surprising that HSV-2 ends up being
able to block apoptosis in a manner similar to HSV-1 since
the genomes of these viruses are colinear and most viral
gene products can functionally substitute for one another
between the two strains (Blaho et al., 1994; Conley et al.,
1981; Knipe et al., 1978, 1981; Morse et al., 1978; Pereira et
al., 1977). Thus, it seems intuitive that viral anti-apoptotic
proteins would likely be similar between HSV-1 and HSV-2.
Consistent with this idea are the reports of the HSV-2 US3
protein having anti-apoptotic activity (Asano et al., 1999;
Hata et al., 1999). In addition, the R1 subunit of the HSV-2
ribonucleotide reductase has been described to be anti-apoptotic (Langelier et al., 2002; Perkins et al., 2003) and
one study has reported that HSV-1 strains deleted for ICP6
have enhanced apoptosis (Langelier et al., 2002). However,
ICP6 is expressed very early during HSV-1 infection and the
impact of its loss on late viral protein accumulation could
explain this effect.
NF-jB translocates to nuclei of HSV-2-infected HEp-2 cells
Upon determining that the HSV-2 and HSV-1 apoptosis
prevention windows were the same, we tested whether the
HSV-2-infected cell proteins produced in that time frame
could block external, environmentally stimulated apoptosis.
We observed that HSV-2 blocked cell death triggered by
Fig. 9. Death factor processing in cells infected with clinical HSV-2
isolates. HEp-2 cells were infected with HSV-1(F), HSV-2(G), HSV-2(333),
and clinical isolates HSV-1(TC), HSV-2(C2), or HSV-2(C9) (MOI of 10
PFU/cell). At 3 hpi, cells were untreated () or CHX (10 Ag/Al) was added
(+) and whole cell extracts were prepared at 20 hpi, separated in a
denaturing gel, transferred to nitrocellulose, and probed with anti-ICP4,
anti-a-tubulin (A), anti-PARP, and anti-caspase-3 (B) antibodies. Percent-
age of PARP cleavage was determined by NIH Image.
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HSV-2 likely blocks other environmental pro-apoptotic
stimuli. In response to TNFa treatment, the cellular
transcription factor NF-nB becomes activated and trans-
locates to the nucleus where it regulates genes which
contribute to the cell’s survival (Beg and Baltimore, 1996;
Beg et al., 1993; Wallach et al., 1999). We observed that
NF-nB was detected in nuclei of HSV-2-infected cells. In
addition, the presence of NF-nB in infected cell nuclei
correlated with apoptosis prevention. That NF-nB was not
nuclear in HSV-2-infected cells when protein translation
was blocked at 3 hpi suggests that early infected cell protein
synthesis is required for NF-nB activation. Similar obser-
vations have been made during HSV-1 infection (Amici et
al., 2001; Goodkin et al., 2003; Medici et al., 2003; Patel et
al., 1998). In the case of HSV-1, NF-nB activation appears
to serve a pro-survival function to ensure productive viral
replication (Gregory et al., 2004). Thus, it is likely that NF-
nB provides a similar function during HSV-2 infection.
Experiments are currently under way to determine whether
the inhibition of nuclear NF-nB reduces the apoptosis
suppression capability of HSV-2.
The induction of apoptosis by HSV-2 differs from that of
HSV-1
The most interesting observation we made was that
maximum apoptosis with HSV-2 was detected when we
blocked protein translation at 3 hpi. It is important to note
that apoptotic features were detected when translation was
prevented at 0 and 1 hpi, but these levels were consistentlyless than that at 3 hpi. One explanation for this is that at
these early times, HSV-2 may not be as potent an apoptotic
inducer as HSV-1. Numerous pieces of evidence argue that
HSV-1 immediate early gene expression is required to
trigger apoptosis (Aubert et al., 1999; Sanfilippo et al.,
2004). If this is also the case for HSV-2, one possible
explanation could be that the level of HSV-2 IE gene
expression is less than that of HSV-1 in these cells.
However, earlier findings that HSV-2 replication occurs
more rapidly and IE protein accumulate to higher levels than
HSV-1 in HeLa cells seem to argue against this idea (Blaho
and Roizman, 1991; Blaho et al., 1994). Another consid-
eration is the fact that HSV-2 has a more potent virion host
shutoff effect than HSV-1 (Fenwick and Walker, 1978;
Fenwick et al., 1979). However, at least under the
conditions utilized in this study, we did not observe any
distinctions between the replication efficiencies of HSV-1
and HSV-2 in our HEp-2 cells. An alternative explanation is
that HSV-2 requires the de novo synthesis of infected cell
protein for optimal apoptosis while HSV-1 does not. This is
an intriguing notion and would represent the first significant
difference in apoptosis modulation between HSV-2 and
HSV-1. The development of appropriate biochemical and
molecular genetic systems should allow the determination of
the molecular basis of the difference in apoptosis induction
between HSV-2 and HSV-1.Methods and materials
Cells and viruses
All cells were maintained and passaged in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 5%
fetal bovine serum. Human epithelial (HEp-2) and African
green monkey kidney (Vero) cells were obtained from the
American Type Culture Collection. The wild-type viruses
HSV-1(F) and HSV-2(G) were provided by Bernard
Roizman, University of Chicago. The clinical strain
HSV-1(TC) was isolated (Bowles et al., 2005) and
provided by Robert Bowles, MSSM, while clinical isolates
HSV-2(C2), HSV-2(C9), and the laboratory strain HSV-
2(333) were provided by Betsy Herold, MSSM. To obtain
virus stocks, subconfluent Vero monolayer cells (approx-
imately 2  106) were inoculated with virus at a
multiplicity of infection (MOI) of 0.01 for 2 h at 37 -C
in 199 V medium (Life Technologies) supplemented with
1% newborn calf serum (NBCS). The inoculum was
removed, fresh DMEM supplemented with 5% NBCS
was added, the cells incubated for 2–3 days at 37 -C in
5% CO2. Virus stocks were prepared once the infection
had reached 100% cytopathic effect, the titer was
determined on Vero cells, and aliquots of virus stored at
80 -C. Detailed previous studies have demonstrated the
induction of HSV-dependent apoptosis is not due to
contaminants present in virus stock preparations (Sanfi-
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of plaque-forming units (PFU) of virus on Vero cells.
Preparation of whole cell extracts
Infected cells were harvested by scraping them off the
dish directly into the medium. After centrifugation for 5 min
at 1000  g, cell pellets were rinsed and resuspended in
phosphate-buffered saline (PBS) containing a 10-AM con-
centration of the following protease inhibitors (all obtained
from Sigma): N-tosyl-l-phenyl-alanine-chloromethylketone
(TPLK), phenylmethylsulfonyl fluoride (PMSF), and tosyl-
l-lysine-chloromethylketone (TLCK). Infected cells were
disrupted by sonication on ice three times for 10 s at an
output of 2 with a Branson sonifier. The protein concen-
tration of each sample was determined by a modified
Bradford protein assay as recommended by the manufac-
turer (BioRad).
Denaturing gel electrophoresis and immunoblotting
technique
Approximately 50 Ag of infected cell protein from whole
cell extracts or subcellular fractions were electrophoretically
separated in a 15% sodium dodecyl sulfate–polyacrylamide
gel cross-linked with N,NV-diallytartardiamide (Blaho and
Roizman, 1998), electrically transferred to nitrocellulose
using a tank apparatus (BioRad), and blocked in 5% milk in
PBS for a minimum of 1 h. Blots were probed with
appropriate primary antibodies (described below) for a
minimum of 1 h. Secondary goat anti-mouse or anti-rabbit
antibodies conjugated to alkaline phosphatase (obtained
from Southern Biotechnology) was then added for 1 h prior
to colorimetric development. Prestained protein molecular
weight markers (purchased from BioRad) were included on
all gels. Immunoblots were digitized (600–800 dots/in.)
with an AGFA Arcus II scanner. Raw digital images were
saved as TIFF image files with Adobe Photoshop and
organized into figures with Adobe Illustrator.
Immunological reagents
The antibodies used to detect viral and cellular proteins
were the following. RGST22 is a rabbit polyclonal antibody
specific for ICP22 (Blaho et al., 1997). H114 is a mouse
monoclonal antibody specific for ICP4 (Goodwin Institute
for Cancer Research). Mouse monoclonal antibody DM-A1
that is specific for a-tubulin was obtained from Sigma.
Mouse monoclonal antibodies specific for caspase-3 and
PARP were obtained from Santa Cruz Biotechnology, Inc.
Mouse monoclonal antibody for NF-nB is generated against
the p65 subunit and was obtained from Santa Cruz
Biotechnology, Inc. Polyclonal goat antibody specific for
Lamin B was purchase from Santa Cruz Biotechnology, Inc.
All primary antibodies used for immunoblotting were used
at a dilution of 1:1000 in 1% BSA. Alkaline phosphatase-conjugated goat anti-rabbit or anti-mouse secondary anti-
bodies were purchased from Southern Biotech, Inc. and
used at 1:1000 dilutions in 1% BSA. Fluorescein isothio-
cyanate (FITC)-conjugated anti-mouse IgG (H + L) was
purchased from Vector Laboratories (Santa Cruz, CA) and
used at dilutions of 1:300 in 1% BSA. AMCA anti-rabbit
IgG (H + L) was purchased from Vector Laboratories and
used at a 1:300 dilution in 1% BSA.
Biochemical and pharmacological reagents: use of CHX
and TNFa
CHX addition at the time of HSV-1 infection inhibits
infected cell protein synthesis, leading to apoptosis of
human HEp-2 cells (Aubert and Blaho, 1999; Goodkin et
al., 2004; Koyama and Adachi, 1997). CHX (10 Ag/ml) was
added to the media of infected cells and maintained until the
cells were harvested. As a positive control for apoptosis,
CHX (10 Ag/ml) and TNFa (10 Ag/ml) were added to mock-
infected HEp-2 cells. Lyophilized TNFa (Sigma) was
dissolved in sterile PBS containing 1% BSA and aliquots
were stored at 80 -C.
DNA laddering assay
Nucleosomal cleavage of cellular DNA was assessed
essentially as described (Aubert and Blaho, 1999). Cells
were scraped into the medium and collected by centrifuga-
tion for 5 min at 1000  g. The cells were rinsed with ice
cold phosphate–saline buffer (PBS) and centrifuged again
to form a cellular pellet. Cells were lysed by resuspending
the pellet in 400 Al of TE (10 mM Tris–HCl, pH 8.0, 10
mM EDTA) containing 0.6% SDS and then mixed with 125
Al of 5 M NaCl. After overnight incubation at 4 -C (to
extract the DNA), the solution was centrifuged for 25 min at
12,000  g to precipitate chromosomal DNA. The super-
natant was collected and sequentially subjected to digestion
with 0.1 mg/ml RNAse A (37 -C for 1 h) and 1 mg/ml
proteinase K (50 -C for 2 h), followed by standard phenol/
chloroform extractions and ethanol precipitation. DNA was
precipitated overnight at 80 -C and samples were
centrifuged at 12,000  g for 20 min. The precipitated
DNAwas separated in a standard 1.5% Tris–borate–EDTA
agarose gel containing 0.1 Ag/ml ethidium bromide and
visualized using UV illumination.
Quantitation of cells with condensed chromatin and
processed death factors
Live cells were stained at 17 hpi with Hoechst 33258
dye (Sigma) at a concentration of 5 Ag/ml for 30 min at
37 -C. Cells with condensed chromatin (visualized by fluoQ
rescence microscopy) as well as the total number of cells
were counted; approximately 150 total cells were counted
for each treatment group. The percentage of apoptotic cells
was calculated as follows: (number of apoptotic cells /
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observed with an Olympus IX70/IX-FLA inverted fluores-
cent microscope and images were acquired using a Sony
DKC-5000 digital photo camera at a resolution of 600–800
dots/in. linked to a PowerMac and processed through
Adobe Photoshop.
During the execution phase of apoptosis, full-length
PARP (116 kDa) is cleaved and the inactive form of
caspase-3 (procaspase-3) becomes cleaved (Aubert et al.,
1999). The PARP antibody used in our study reacts with
both the full-length form and its 85-kDa cleavage product.
While our caspase-3 antibody recognizes the uncleaved
form (32 kDa) and one of the processed forms (20 kDa),
under our gel electrophoresis conditions, only the uncleaved
(inactive) form is resolved. Therefore, the loss of caspase-3
reactivity corresponds to apoptosis induction in our system
(Aubert et al., 1999). PARP cleavage was quantitated as
described (Aubert et al., 2001; Nguyen et al., 2005) using
the public domain NIH Image computer application
(developed at the National Institutes of Health and available
on the Internet at http://www.rsb.info.nih.gov/nih-image).
Integrated densities (ID) of the 116,000 mol. wt. uncleaved
and 85,000 mol. wt. cleaved PARP were determined and %
PARP cleavage was calculated using the following formula:
% cleaved = {(cleaved PARP ID) / (cleaved PARP ID plus
uncleaved PARP ID)}. Each experiment was performed at
least two times.
Indirect immunofluorescence
HEp-2 cells were prepared for indirect immunofluor-
escence as previously described (Pomeranz and Blaho,
1999; Yedowitz et al., 2005). Briefly, cells were rinsed
twice with non-sterile PBS, fixed in 2.5% methanol-free
formaldehyde (Polysciences, Inc.) for 20 min at room
temperature. Cells were again rinsed twice with PBS and
permeablized with 100% acetone at 20 -C for 4 min.
Cells were rinsed with PBS and incubated overnight with
1% BSA supplemented with 10 Ag of pooled human
immunoglobulin (Ig; Sigma) per ml. Treatment with Ig was
previously shown to sufficiently neutralize Fc binding by
the viral gE and gI proteins (Kotsakis et al., 2001). Primary
antibodies used for indirect immunofluorescence were
diluted and added for 1 h; mouse monoclonal NF-nB
antibody and rabbit polyclonal ICP22 were both diluted
1:500. After rinsing twice with PBS, the appropriate
secondary antibody was added to the cells and incubated
for 45 min in the dark. After the cells were again rinsed
twice with PBS, they were preserved with Prolong
Antifade (Molecular Probes) as an anti-bleaching agent,
mounted on a fresh glass slide, and stored at 4 -C for at
least 4 h. Cells were visualized on an Olympus IX70/IX-
FLA inverted fluorescence microscope and images were
acquired at a resolution of 600–800 dots/in. using a Sony
DKC-5000 digital photo camera linked to a PowerMac.
Raw digital images were saved as tagged image files (TIF)with Adobe Photoshop, organized into figures with Adobe
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